NRx Pharmaceuticals, Inc. (NRXP)

3,5400 +0,0200 (+0,57%) Börsenschluss: 04:00PM EDT

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
(484) 254-6134
https://www.nrxpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jonathan C. Javitt M.D., M.P.H.	Co-Founder, Chief Scientist Officer & Chairman	630,2k	N/A	1957
Mr. Stephen H. Willard Esq.	Acting Corporate Secretary, CEO & Director	500k	N/A	1961
Mr. Richard Clavano Narido	CFO & Treasurer	255,01k	N/A	1979
Dr. Riccardo Panicucci Ph.D.	Chief Manufacturing & Technology Officer	240k	N/A	1961
Suzanne Messere	Investor Relations	N/A	N/A	N/A
Dr. Philip T. Lavin Ph.D.	Chief Methodologist	N/A	N/A	1947
Dr. Dennis K. McBride Ph.D.	Chief Strategy Officer & Senior Scientist	N/A	N/A	N/A
Mr. Matthew Patrick Duffy	Chief Business Officer	N/A	N/A	1963

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate Governance

NRx Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.